Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases

Introduction: The effectiveness of bowel cleansing is a key element for high-quality colonoscopy. Recently, a 1 L polyethylene glycol plus ascorbate (PEG-ASC) solution has been introduced, but effectiveness and safety of this preparation have not been assessed in IBD patients. This study aims to evaluate effectiveness and safety of 1 L PEG-ASC solution in patients with IBD compared to controls. Methods: We retrospectively analysed prospectively collected data on a cohort of 411 patients performing a colonoscopy after preparation with 1 L PEG-ASC, consecutively enrolled in 5 Italian centres. Results: Overall, 185/411 (45%) were patients with IBD and 226/411 (55%) served as controls. A sig-nificantly higher cleansing success was achieved in IBD patients (92.9% vs 85.4%, p = 0.02). The multi-ple regression model showed that presence of IBD (OR = 2.514, 95%CI= 1.165-5.426; P = 0.019), lower age (OR = 0.981, 95%CI= 0.967-0.996; P = 0.014), split preparation (OR = 2.430, 95%CI= 1.076-5.492; P = 0.033), absence of diabetes (OR = 2.848, 95%CI= 1.228-6.605; P = 0.015), and of chronic constipation (OR = 3.350, 95%CI= 1.429-7.852; P = 0.005), were independently associated with cleansing success. The number of treatment-emergent adverse events (TEAEs) (51 vs 62%, p = 0.821), and of patients with TEAEs (22.2% vs 21.2%, p = 0.821), were similar in IBD patients and in controls, respectively. Conclusions: Results from this study support the effectiveness and safety of 1 L PEG-ASC solution in IBD patients, which may improve the definition of endoscopic outcomes both in Crohn's disease and ulcera-tive colitis. (c) 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Automated summary

The study evaluated the effectiveness and safety of 1 L PEG-ASC solution in IBD patients, showing higher cleansing success in IBD patients compared to controls. Factors associated with cleansing success in IBD patients included younger age, split preparation, absence of diabetes, and chronic constipation. Treatment-emergent adverse events were similar between IBD patients and controls.